A year after the identification of the JAK2 mutation as a pivotal factor in the pathogenesis of myeloproliferative neoplasms (MPN), researchers began to investigate patients lacking JAK2 alterations. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.